Harrow Reports 58% Reduction in Patient-Reported Discomfort with IHEEZO®
NASHVILLE, Tennessee, August 20, 2026 Harrow, Inc. announced positive results from a prospective, randomized contralateral-eye study evaluating IHEEZO® (chloroprocaine...
Retinal Diseases
Advertisement
Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA
ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...
Samsung Bioepis and Harrow Strengthen SB11 Clinical Evidence
INCHEON, South Korea & NASHVILLE, Tenn., July 20, 2026 Samsung Bioepis Co., Ltd. and Harrow, Inc. have presented positive...
REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
Xbrane Nears FDA Decision for Lucamzi Biosimilar
STOCKHOLM, Sweden, June 3, 2026 Xbrane Biopharma AB has reached a significant regulatory milestone after the U.S. Food and...
Advertisements
Teva Launches AHZANTIVE Biosimilar to Eylea Across Europe
TEL AVIV, Israel, June 4, 2026 Teva Pharmaceutical Industries Ltd. has announced the European launch of AHZANTIVE® (aflibercept), an...
Opus Genetics Enters FDA RDEP Program for OPGx-LCA5
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
Ocugen OCU410 Gene Therapy Cuts GA Progression
MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...
KSI-101 Phase 1b Data Advance Inflammatory Macular Therapy
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
Advertisement
